Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
+0.01 (0.02%)
After Hours: 40.01 0.00 (0.00%)
Nov 24, 4:23PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.52 - 40.12
52 week 25.26 - 43.00
Open 39.86
Vol / Avg. 0.00/2.55M
Mkt cap 11.32B
P/E 88.59
Div/yield     -
EPS 0.45
Shares 282.91M
Beta 1.12
Inst. own 98%
Jan 26, 2016
Q1 2016 Hologic Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 2, 2015
Hologic Inc at Piper Jaffray Healthcare Conference Add to calendar
Nov 10, 2015
Hologic Inc at Mitsubishi UFJ Securities Healthcare Conference
Nov 4, 2015
Q4 2015 Hologic Inc Earnings Call - Webcast
Nov 4, 2015
Q4 2015 Hologic Inc Earnings Release
Sep 16, 2015
Hologic Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 3.59% 4.87%
Operating margin 12.51% 14.51%
EBITD margin - 36.04%
Return on average assets 1.28% 1.64%
Return on average equity 4.68% 6.35%
Employees 5,351 -
CDP Score - -


250 Campus Dr
MARLBOROUGH, MA 01752-3020
United States - Map
+1-508-2632900 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Company’s business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Officers and directors

Stephen P. MacMillan Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Claus Egstrand Senior Vice President, General Manager - International
Age: 53
Bio & Compensation  - Reuters
Allison Bebo Senior Vice President - Human Resources
Bio & Compensation  - Reuters
John Griffin General Counsel
Bio & Compensation  - Reuters
Elaine S. Ullian Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Jonathan N. Christodoro Independent Director
Age: 39
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters